Ovarian cancer diagnosis and treatment

Using targeted therapy to promote a pro-inflammatory tumour microenvironment and anti-tumour immune response in high grade serous ovarian cancer

This study evaluates CHK1i+LDHU therapy in HGSOC, showing it kills cancer cells and reprograms the tumor microenvironment to enhance anti-tumor immune responses.

Comparative single-cell atlases reveal injury-driven tubal epithelial regeneration as a window for ovarian carcinoma initiation

The paper compares single-cell transcriptomes of mouse and human tubal epithelium to show injury-driven regeneration in humans may contribute to ovarian cancer initiation.

MRPL47 as a Novel Mitochondrial Biomarker for Early Detection and Therapeutic Response in Ovarian Cancer

This study identifies MRPL47 as a biomarker for ovarian cancer, showing its association with poor survival, metabolic changes, and therapeutic response.

Single-Cell Transcriptomic Signatures Enable Stratified Combination Therapy for Platinum-Resistant Ovarian Cancer

The paper uses single-cell RNA sequencing to identify resistance signatures in ovarian cancer and develops a framework for combination therapy with carboplatin.

Matrix structure and microenvironment dynamics correlate with chemotherapy response in ovarian cancer

The paper shows that modifying the tumor microenvironment's extracellular matrix improves chemotherapy response in ovarian cancer models.

Single-cell spatial atlas of high-grade serous ovarian cancer unveils MHC class II as a key driver of spatial tumor ecosystems and clinical outcomes

Cyclic immunofluorescence of 265 high-grade serous ovarian carcinomas and random-forest feature ranking identify cancer-cell MHC-II as an adjusted predictor of longer survival marking immune-activated tumor-stroma hotspots.

Establishment of a humanized patient-derived xenograft mouse model of high-grade serous ovarian cancer for preclinical evaluation of combination immunotherapy

This study develops a humanized xenograft model of high-grade serous ovarian cancer to evaluate immunotherapy, finding no treatment response but identifying immune-excluded tumor phenotypes.

Stromal estrogen signaling regulates fallopian tube homeostasis and cancer initiation via inflammatory pathways

This study shows that estrogen receptor signaling in fallopian tube stromal cells maintains epithelial homeostasis by promoting proliferation and ciliated differentiation, but excessive estrogen shifts this niche toward inflammation and stemness, contributing to cancer initiation.

Deconvolved tumor adipocyte proportions and high grade serous ovarian carcinoma survival

The paper deconvolves adipocyte proportions from bulk RNA-seq data of HGSOC tumors and finds higher adipocyte content is associated with worse survival.

IdentifiHR: predicting homologous recombination deficiency in high-grade serous ovarian carcinoma using gene expression

IdentifiHR predicts homologous recombination deficiency in high-grade serous ovarian carcinoma using gene expression, achieving 85% accuracy in TCGA and 91% in an independent cohort.

Connecting mitochondrial metabolism and mitotic fidelity to control vulnerability of high grade serous ovarian cancer patients to taxane-based chemotherapy

This paper identifies syntabulin as a determinant of chemosensitivity in high-grade serous ovarian cancer by linking mitochondrial metabolism and mitotic fidelity.

Simpler predictive models provide higher accuracy for ovarian cancer detection

This paper demonstrates that a simpler logistic regression model using protein biomarkers outperforms a more complex method incorporating cfDNA features in ovarian cancer detection.

Comparative proteomic analysis of the ECM composition of the human omentum and mesentery, the main sites of ovarian cancer metastasis

This study compares the extracellular matrix composition of the human omentum and mesentery using proteomics to identify potential factors contributing to ovarian cancer metastasis.

Combined inhibition of NAD synthesis and C-terminal binding protein cooperatively induce cell death and inhibit growth of High Grade Serous Ovarian Carcinoma

The paper shows that combining CtBP inhibitors with NAD synthesis inhibitors enhances cell death and inhibits growth of high-grade serous ovarian carcinoma.

Co-targeting the PI3K-Akt pathway improves response to MEK inhibition in low-grade serous ovarian cancer cell lines

This study shows that combining MEK and PI3K-Akt inhibition enhances anti-tumor effects in LGSOC cells and may overcome resistance to MEK inhibitors.

The prion-like protein Doppel: A soluble biomarker steering ovarian cancers peritoneal to circulatory dissemination

This paper identifies Doppel as a specific biomarker for ovarian cancer, showing its association with tumor subtypes, early detection, and dissemination mechanisms.

Effects of a novel proteasome inhibitor, UR238 on the tumor immune microenvironment and growth in epithelial ovarian cancer

Generation of an in vitro 3D multicellular culture model of ovarian high-grade serous carcinoma

This paper describes a protocol to generate a 3D multicellular model of ovarian high-grade serous carcinoma that includes stromal cells and organoids for drug testing and scRNA-seq.

MEX3A control of mitochondrial fitness is essential for ovarian clear cell carcinoma tumorigenesis and liver metastasis

This study shows MEX3A promotes ovarian clear cell carcinoma tumorigenesis and liver metastasis by maintaining mitochondrial fitness independently of p53.

Rete Ovarii Epithelial Cells as an Unappreciated Cell of Origin for Pelvic and Ovarian High-Grade Serous Carcinoma

This study identifies rete ovarii epithelial cells as a new cell of origin for high-grade serous carcinoma, showing their ability to drive malignant transformation and produce tumors with HGSC-like features.

BMAL2 is a druggable target for ARID1A-wildtype ovarian clear cell carcinoma (OCCC)

This study identifies BMAL2 as a therapeutic target for ARID1A-wt ovarian clear cell carcinoma, showing that its depletion or degradation reduces tumor growth and DNA damage.

Quantitative Proteomics Identifies Conserved Proteins and Altered Regulation of Mucin-16 in Low Grade Serous Ovarian Cancers

The paper identifies conserved protein alterations and elevated MUC16 in low-grade serous ovarian cancers through quantitative proteomics and validation across multiple datasets.

Development and validation of a computational tool to predict treatment outcomes in cells from High-Grade Serous Ovarian Cancer patients

The paper develops and validates a computational tool to predict treatment outcomes in HGSOC cells, showing its potential for preclinical research and personalized medicine.

Glycomics Profiling Reveals a Stromal Chondroitin-4-sulfate State that Shapes Platinum Response in Ovarian Cancer

This study identifies stromal chondroitin-4-sulfate as a determinant of platinum response in ovarian cancer through glycomics profiling and functional validation.

Organoid Models Derived from Primary Tumors and Patient-Derive Xenograft Tumors Reflect Platinum Sensitivity of Ovarian Cancer Patients

This study shows that organoids derived from patient-derived xenografts (PDXOs) reflect the chemotherapy response of ovarian cancer patients similarly to organoids directly from primary tumors (PDOs).

FSTL3 is a biomarker of poor prognosis and is associated with immunotherapy resistance in ovarian cancer.

This study identifies FSTL3 as a biomarker of poor prognosis and immunotherapy resistance in ovarian cancer, showing its role in promoting a mesenchymal phenotype and immunosuppressive microenvironment.

Integrated Human Transcriptomics Identifies Fallopian Tube Progenitors as Plausible Precursors of High-Grade Serous Ovarian Cancer

The paper identifies fallopian tube progenitors as potential precursors of high-grade serous ovarian cancer by integrating transcriptomic data from normal and malignant tissues.

A Rare Multipotent Peg-like Epithelial Cell is a Candidate Cell-of-Origin for High-Grade Serous Ovarian Cancer

The paper identifies a rare multipotent epithelial cell in the fallopian tube as a potential cell-of-origin for high-grade serous ovarian cancer using multi-omic profiling and organoid models.

3D multi-omic mapping of whole nondiseased human fallopian tubes at cellular resolution reveals a large incidence of ovarian cancer precursors

The paper presents a 3D multi-omic framework to detect and characterize ovarian cancer precursors in fallopian tubes, identifying TP53 mutations in microscopic lesions.

Surface proteomics reveals arginine metabolism as a vulnerability in high grade serous ovarian cancer

This study identifies SLC7A1 and arginine metabolism as a therapeutic vulnerability in high-grade serous ovarian cancer through surface proteomics and functional analysis.